We advised Adagene on the offering

Davis Polk advised Adagene Inc. in connection with its $70 million SEC-registered direct offering of American depositary shares (ADSs). Adagene’s ADSs are listed on the Nasdaq under the ticker symbol “ADAG.”

Adagene is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies.

The Davis Polk capital markets team included partner Xuelin (Steve) Wang, counsel - registered foreign lawyer Xin (Sheen) Xu and registered foreign lawyer Linfei Li. The tax team included partner Patrick E. Sigmon, counsel Alon Gurfinkel and associate Fred (Chen) Fu. Members of the Davis Polk team are based in the Hong Kong, New York and London offices.

Copy link to share post